Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology Meeting
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nextech3D.ai Announces CEO Evan Gappelberg Acquires 550,000 Shares of Company Stock In Open Market Buys
Fortune Minerals Announces Additional Government Support to Help Purchase the NICO Alberta Refinery Site